Combining gefitinib and AZD5363 demonstrated synergistic growth inhibition in EGFR-mutant (HCC-827 and PC-9) and wild-type (NCI-H522, NCI-H1651) NSCLC cell lines. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.